Elena Bruzzesi
Overview
Explore the profile of Elena Bruzzesi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
182
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Raccagni A, Passini F, Bruzzesi E, Badalucco Ciotta F, Bossolasco S, Castagna A, et al.
Sex Transm Infect
. 2025 Mar;
PMID: 40081909
No abstract available.
2.
Taramasso L, Rossotti R, Tavelli A, Santoro M, Mazzotta V, Bandera A, et al.
J Acquir Immune Defic Syndr
. 2025 Feb;
98(4):352-356.
PMID: 39970315
Background: The best therapeutic management for people with HIV (PWH) who have a history of preexposure prophylaxis (PrEP) is still debated. Objectives: The aim of this study was to describe...
3.
Bruzzesi E, Gandini F, Diotallevi S, Lolatto R, Cernuschi M, Candela C, et al.
Microorganisms
. 2025 Jan;
12(12.
PMID: 39770774
Men who have sex with men (MSM) and people with HIV are at increased risk of anal HPV infection and cancer. This study aimed to assess the prevalence of anal...
4.
Lisac L, Raccagni A, Lolatto R, Passini F, Maci C, Bruzzesi E, et al.
Viruses
. 2024 Nov;
16(11).
PMID: 39599903
Genital herpes simplex virus (HSV) is associated with a reduction in quality of life and adverse outcomes. The aim of this study is to assess the interest and expectations for...
5.
Raccagni A, Passini F, Diotallevi S, Lolatto R, Bruzzesi E, Piromalli G, et al.
J Acquir Immune Defic Syndr
. 2024 Nov;
98(1):37-40.
PMID: 39579112
Background: The aim of this study is to assess the acceptability of HIV preexposure prophylaxis (PrEP) among individuals eligible for prophylaxis. Setting: Retrospective study of individuals receiving their first HIV...
6.
Raccagni A, Diotallevi S, Lolatto R, Bruzzesi E, Catalano G, Mainardi I, et al.
Lancet Infect Dis
. 2024 Nov;
25(1):e1-e3.
PMID: 39577454
No abstract available.
7.
Bruzzesi E, Muccini C, Castagna A
Expert Opin Drug Metab Toxicol
. 2024 Nov;
:1-8.
PMID: 39530796
Introduction: The combination of bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF) represents a valid option of antiretroviral therapy (ART) as first line regimen both in ART-naïve and -experienced people with HIV...
8.
Raccagni A, Diotallevi S, Lolatto R, Bruzzesi E, Martearena Garcia M, Mainardi I, et al.
Open Forum Infect Dis
. 2024 Nov;
11(11):ofae562.
PMID: 39498171
Background: 4CMenB appears to be effective in reducing (Ng) infections. Aims are to assess factors associated with breakthrough rectal Ng after 4CMenB and evaluate clinical and microbiological characteristics of breakthrough...
9.
Calcagno A, Cusato J, Cinque P, Marchetti G, Bernasconi D, Trunfio M, et al.
Brain
. 2024 Aug;
147(11):3742-3750.
PMID: 39171829
It is debated whether CNS involvement begins during acute human immunodeficiency virus (HIV) infection in persons without meningitis/encephalitis and whether specific antiretroviral drugs or combinations would be beneficial. Neurologically asymptomatic...
10.
Raccagni A, Siribelli A, Diotallevi S, Sampaolo M, Bruzzesi E, Clementi N, et al.
Sex Transm Dis
. 2024 Aug;
51(12):772-774.
PMID: 39102506
This is a retrospective study on men who have sex with men (MSM) diagnosed with rectal lymphogranuloma venereum (LGV), treated with 7 or 21 days of doxycycline between 2015 and...